Cancer News and Research

Latest Cancer News and Research

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

First Edition: August 9, 2010

Today's health policy headlines include dispatches from the campaign trail, news of the President's weekly address and developments from the health care marketplace.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Aquilion ONE 320-detector row CT system reduces radiation exposure

When pediatric patients are imaged using CT, reducing sedation and radiation dose while maintaining the best possible image quality is paramount in delivering care. To provide patients with high-quality CT exams and a reduction in sedation and radiation dose, leading children's hospitals are installing Toshiba America Medical Systems, Inc.'s Aquilion ONE 320-detector row CT system.

9 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

Magnetic relaxometry with heat treatment improves treatment of tumours by nanoparticles

Those who have to fight a powerful enemy must look for allies. This is why physicists from different scientific fields have decided to cooperate with biomedical physicians in order to place the fight against cancer through heat treatment by means of magnetic nanoparticles on a solid, scientific basis. It is the objective of the cooperation to improve the success of the therapy.

9 Aug 2010

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

9 Aug 2010

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

9 Aug 2010

GWA Study helps scientists identify genetic variant that increases tuberculosis susceptibility in African populations

Scientists have identified a genetic variant which increases susceptibility to tuberculosis (TB) in African populations using a technique known as a genome-wide association (GWA) study. This is the first novel disease variant to be identified using this technique in Africans and demonstrates that such studies are viable in African populations, which have a high degree of genetic diversity.

9 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

ADVENTRX second-quarter net loss applicable to common stock increases to $5.0 million

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

Oil Can Henry's customers rose to the challenge in July and helped the company raise $45,401 to support the Oregon and SW Washington Affiliate of Susan G. Komen for the Cure to help save lives and end breast cancer. Over the week-long fundraising effort, Oil Can Henry's locations in Oregon and Southwest Washington performed oil changes on 15,746 vehicles. In addition, customers had the opportunity to donate directly to Komen at the time of service.

7 Aug 2010

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010.

7 Aug 2010

Patient navigator program to educate Hmong women on cervical cancer

The Asian-American community of Hmong women in California carries a stunning burden of cervical cancer and resulting mortality four times as high as non-Hispanic white women in California do.

7 Aug 2010

US Department of Justice closes investigation of proposed Phase Forward acquisition by Oracle

Phase Forward Incorporated, a leading provider of data management solutions for clinical trials and drug safety, announced that the United States Department of Justice has closed its investigation of the proposed acquisition of Phase Forward by Oracle Corporation, and that the waiting period under the Hard-Scott-Rodino Antitrust Improvements Act of 1976 regarding the Merger has been terminated.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

7 Aug 2010

Cancer News and Research

Latest Cancer News and Research

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

First Edition: August 9, 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Aquilion ONE 320-detector row CT system reduces radiation exposure

Repros Therapeutics receives positive feedback from FDA for Androxal

Magnetic relaxometry with heat treatment improves treatment of tumours by nanoparticles

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

GWA Study helps scientists identify genetic variant that increases tuberculosis susceptibility in African populations

EpiCept second-quarter net loss decreases to $4.9 million

ADVENTRX second-quarter net loss applicable to common stock increases to $5.0 million

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Patient navigator program to educate Hmong women on cervical cancer

US Department of Justice closes investigation of proposed Phase Forward acquisition by Oracle

Halozyme second-quarter revenue increases to $3.2 million

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Understanding the DNA Damage Response in Innate Immunity eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in